Compare NP & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | ICUI |
|---|---|---|
| Founded | 2017 | 1984 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Specialty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | N/A | 1995 |
| Metric | NP | ICUI |
|---|---|---|
| Price | $25.08 | $130.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | $28.17 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 864.9K | 269.6K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $25.84 | N/A |
| Revenue Next Year | $15.80 | $4.46 |
| P/E Ratio | ★ N/A | $109.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.78 | $107.02 |
| 52 Week High | $31.75 | $160.29 |
| Indicator | NP | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 54.41 |
| Support Level | $24.16 | $115.74 |
| Resistance Level | $26.85 | $132.83 |
| Average True Range (ATR) | 1.46 | 4.89 |
| MACD | -0.32 | 0.87 |
| Stochastic Oscillator | 10.25 | 54.29 |
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.